糖尿病性腎疾患患者の尿中タンパク質排泄に対する薬剤 R3R01 の評価。 (Kidney ABC)
糖尿病性腎疾患におけるアルブミン尿レベルに対するABCA1誘導剤R3R01の効果
The goal of this clinical trial is to to investigate whether the drug R3R01 has a beneficial effect on the amount of protein excreted in the urine in adult patients (above 18 years of age) with type 2 diabetes and resulting kidney disease.
The main questions it aims to answer are:
- Does 3 months of treatment with 200mg of the drug R3R01 morning and evening have a beneficial effect on the amount of protein excreted in the urine in patients with type 2 diabetes and kidney disease?
- Does R3R01 have an effect on kidney function and daily blood pressure?
Researchers will compare the results of 40 people who take R3R01 to 20 people who receive an inactive substance (placebo).
Participants will receive R3R01 or the placebo as an oral tablet and undergo a selection of medical examinations - such as:
- blood samples
- urine tests
- kidney tests involving a radiolabelled marker which is injected into the bloodstream and monitored via blood samples
- 24 hour blood pressure monitoring via a wearable device
- urine pregnancy test (if applicable)
調査の概要
詳細な説明
An increasing amount of evidence suggests that lipid dysmetabolism and accumulation in the kidneys play a central role in the pathogenesis of kidney disease. This lipotoxicity, in turn, may contribute to the development of albuminuria and chronic kidney disease.
One may surmise that interventions that reduce or prevent the progression of kidney lipid accumulation protect against the progression of kidney disease, including diabetic kidney disease (DKD). Therefore, it is possible inhibiting cholesterol absorption, might effectively protect against lipid accumulation and related disease in the kidneys.
R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney.
Persons with type 2 diabetes with moderate and severe albuminuria have a poor renal and cardiovascular prognosis. As albuminuria is viewed both as a risk marker but also as a target for intervention, any treatment with antiproteinuric effects could be beneficial. The role of ABCA1 inducer treatment on kidney parameters in diabetic kidney disease is not known. By investigating the impact of ABCA1 inducer treatment on albuminuria, it will be determined whether this intervention may represent a future treatment option.
This study is a single center, double-blind, placebo controlled, parallel group randomized (2:1) study, in 60 people with type 2 diabetes with moderate or severe albuminuria and estimated glomerular filtration rate (eGFR) above 30 ml/min/1.73m2. 40 people will take R3R01 whilst 20 people receive the placebo.
The study's primary objective is to evaluate the effect of 12 weeks treatment with R3R01 on albuminuria in the study population. In addition to a 12 week treatment period, there will be a follow-up period of approximately 24 weeks (168 days). The expected total duration of study participation is up to 36 weeks for each patient.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究連絡先
- 名前:Minh-Nguyêt Duong
- 電話番号:+31628443389
- メール:mnduong@narrowrivermgmt.com
研究場所
-
-
Copenhagen
-
Copenhagen、Copenhagen、デンマーク、2730
- 募集
- Steno Diabetes Center Copenhagen
-
コンタクト:
- Peter Rossing, Professor
- 電話番号:+30913383
- メール:Peter.Rossing@regionh.dk
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults (above 18 years of age) with controlled type 2 diabetes (hemoglobin A1c less than 10.5%).
- Stable antihypertensive treatment 4 weeks before start of study drug and throughout study duration.
- Titrated to the maximal dose or maximal tolerated dose of renin-angiotensin blocking treatment.
- Stable treatment with lipid lowering agents for at least 4 weeks.
- People on SGLT2-Inhibitors should be on a stable dose of the drug for at least 3 months.
- UACR >30 mg/g and < 5000 mg/g on two consecutive measurements.
- eGFR >30 ml/min/1.73 m2 (CKD-EPIcrea formula).
- Abdominal obesity Women: > 80 cm, Men: > 95 cm or fasting triglyceride >2.0 mmol/l.
- Systolic blood pressure ≥110 mmHg and ≤160 mmHg.
- Both female patients, as well as female partners of male patients who are of child-bearing potential must be willing to not become pregnant for the complete duration of the study and 90 days after the last dose of study medication.
- Males (including sterilized subjects) whose female partners have child-bearing potential, must agree to use male contraception (condoms) during the period from the time of signing the informed consent form through 90 days after the last dose of study drug. They must agree to immediately inform the investigator if their partner becomes pregnant during the study.
Exclusion Criteria:
- Polycystic kidney disease, ANCA-associated vasculitis, or lupus nephritis.
- Ongoing cancer treatment.
- Immunosuppressive therapy or immunosuppression the prior 6 months.
- Nephrotic syndrome.
- Impaired liver function (clinically significant).
- Pregnancy or lactation.
- Failure to understand patient information or to collaborate with the investigator.
- Females of childbearing potential (those who are not surgically sterilized or post-menopausal for at least 1 year) are excluded from participation in the study unless they agree to use highly effective contraception.
- History of hypersensitivity to study drug and/or any of its excipients.
- Hereditary galactose intolerance, total lactase deficiency or glucose-galactose malabsorption.
- Active or planned treatment with a medication that interacts with R3R01.
- Any other medical condition(s) that might put the patient at risk or influence study results in the investigators opinion, or that the investigator deems unsuitable for the study including drug or alcohol abuse or psychiatric, behavioral, or cognitive disorders sufficient to interfere with the patient's ability to understand and comply with the protocol instructions or follow-up procedures.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:R3R01
R3R01 oral tablet (200 mg twice daily) for 12 weeks |
R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information. |
|
プラセボコンパレーター:Placebo
Placebo oral tablet twice daily for 12 weeks |
Please refer to arm/group description for further information. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Urinary albumin-to-creatinine ratio (UACR)
時間枠:12 weeks (84 days)
|
Urinary albumin-to-creatinine ratio (UACR) (Change from baseline to end of treatment at 12 weeks (84 days). |
12 weeks (84 days)
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Measured or Estimated Glomerular Filtration Rate
時間枠:12 weeks (84 days)
|
Measured glomerular filtration rate (GFR) with plasma clearance of 99Tc-DTPA or eGFR measured with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation based on creatinine and/or cystatin C (change from baseline to end of treatment at 12 weeks (84 days)). |
12 weeks (84 days)
|
|
24 hours ambulatory blood pressure
時間枠:12 weeks (84 days)
|
24 hours ambulatory blood pressure (change from baseline to end of treatment at 12 weeks (84 days)). |
12 weeks (84 days)
|
|
Plasma Pharmacokinetics
時間枠:24 weeks (168 days)
|
R3R01 plasma concentrations will be measured to determine Maximum plasma concentration (Cmax) |
24 weeks (168 days)
|
|
Plasma Pharmacokinetics
時間枠:24 weeks (168 days)
|
R3R01 plasma concentrations will be measured to determine minimum blood plasma concentration (Cmin) |
24 weeks (168 days)
|
|
Plasma Pharmacokinetics
時間枠:24 weeks (168 days)
|
R3R01 plasma concentrations will be measured to determine the half-life (T1/2) |
24 weeks (168 days)
|
協力者と研究者
スポンサー
協力者
捜査官
- 主任研究者:Peter Rossing, dr.med.、Steno Diabetes Center Copenhagen
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- R3R01-DKD-201
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。